THE PURSUIT OF PROGRESS
We redefine possibilities. At QIAGEN, we believe every insight contributes vital momentum to making improvements in life possible. This drives us to create, innovate and deliver solutions that propel our customers forward in their mission to make a difference. By powering life science research from sample to insight, QIAGEN is an impactful partner in the pursuit of progress.
Further information can be found at http://www.qiagen.com.
Dr. Brian Adams, PhD Instructor
Tutorial Video Abstract
In this webinar you will learn:
- How to sensitively, specifically and rapidly analyze circulating free nucleic acids (cfDNA), circulating tumor cells (CTCs) or exosomes from a blood sample using liquid biopsy
- About miRNA signatures and how they have the potential to serve as biomarkers for disease pathogenesis, prognosis, and response to treatment.
- How to overcome problems with low abundance and contamination in isolating miRNAs from biofluids.
Recently, there has been a push to develop alternative methods to traditional invasive techniques, such as solid tissue biopsies, for disease diagnosis and disease progression, as well as therapeutic response. Liquid biopsy is a new, minimally invasive technology for detecting circulating biomarkers without the need for costly or invasive procedures. Liquid biopsy enables users to sensitively, specifically and rapidly analyze circulating free nucleic acids (cfDNA), circulating tumor cells (CTCs) or exosomes from a blood sample.
miRNAs are involved in almost every regulatory process and are often secreted into various bodily fluids, such as blood, saliva, and urine. Secreted miRNA level and type are often altered during the course of pathologies and, again, by treatment. This generates a new miRNA signature and is unique to that state of disease development. These miRNA signatures have the potential to serve as biomarkers for disease pathogenesis, prognosis, and response to treatment.
New challenges face scientists who isolate miRNAs and other biomarkers from various bodily fluids. Often there is the issue of contamination from the biofluid and, generally, miRNAs are in low abundance. Additionally, different fluids require different methods to optimally isolate the biomarker. Here we will discuss how to overcome these obstacles in isolating miRNAs from biofluids.